Concordance of CPS score in head and neck squamous cell carcinoma with different PD-L1 de-tection antibodies
Objectives To assess the concordance of PD-L1 CPS scores in head and neck squamous cell carcinoma specimens using the 22C3 pharmDx and SP263 aassy.Methods A prospective study was conducted on 55 head and neck squamous cell carcinoma specimens diagnosed in the pathology department.Immunohistochemical methods were utilized to detect PD-L1 expression.The positive detection rates of PD-L1 CPS scores using the 22C3 pharmDx and SP263 aassy were compared,and the concordance of PD-L1 CPS scores between the two assays was analyzed.Results There was no significant correlation between PD-L1 expression rate and patient age,tumor location,staging,and grading(P＞0.05).Strong positive correlation was observed between PD-L1 CPS scores obtained with the 22C3 pharmDx and SP263 assays(Spearman correlation coefficient=0.979,P＜0.01).Both assays demonstrated high concordance in PD-L1 CPS scores when CPS cut-offs were set at≥1 and ≥20(Cohen's Kappa values of 0.61 and 0.66,respectively).Conclusion The an-tibodies 22C3 pharmDx and SP263 exhibits high consistency in PD-L1 expression in head and neck squamous cell carci-noma.The assessment results of PD-L1 CPS using these two antibodies can be interchangeably used when selecting im-mune therapy for patients with head and neck squamous cell carcinoma,providing additional options for PD-L1 CPS test-ing.
PD-L122C3SP263Combined positive scoreHead and neck squamous cell carcinoma
万方数据
维普
